Annals of Indian Academy of Neurology
  Users Online: 248 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size
REVIEW: MANAGEMENT UPDATES
Year : 2009  |  Volume : 12  |  Issue : 4  |  Page : 283-290

Promising treatments of tomorrow for multiple sclerosis


Johns Hopkins Multiple Sclerosis Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Correspondence Address:
Daniel M Harrison
Johns Hopkins Multiple Sclerosis Center, Johns Hopkins University, School of Medicine, 600 North Wolfe Street Pathology 627, Baltimore, Maryland 21287
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-2327.58279

Rights and Permissions

The therapeutic options for multiple sclerosis are rapidly expanding. What was once seen as a disease with little hope for treatment is now a target of rapid drug development. Current therapies have demonstrated efficacy in limiting the impact of the disease, but none is fully effective in all patients. However, promising new treatments are on the horizon. In this review we will discuss potential novel immunomodulating drugs that are in advanced stages of investigation; these drugs include monoclonal antibodies, chimeric molecules, and oral therapies. The use of hematopoietic stem cells will also be discussed and, in addition, we will look farther ahead at possible novel targets for the development of new immunomodulatory or neuroprotective pharmaceuticals.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3710    
    Printed148    
    Emailed4    
    PDF Downloaded207    
    Comments [Add]    
    Cited by others 3    

Recommend this journal